Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • New antibodies neutralize resistant bacteria

    Broadly neutralizing antibodies are already being used to fight viruses. This approach could also help to treat infections with multi-resistant bacteria in the future / publication in the renowned journal ‘Cell’

  • Abbott Receives FDA Approval for HPV Test to Run on Alinity M

    Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

  • Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg

    Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.

  • Protein interaction causing rare but deadly vaccine-related clotting found

    A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research.

    In a recent paper published in Blood, scientists from the University of Birmingham funded by the National Institute for Health and Care Research and the British Heart Foundation have been able to identify how deadly blood clots, in the disease known as Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT), occur.

  • Zydus acquires UK based LiqMeds Group

    Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

  • Intercharm Moscow 2023, International exhibition for perfumery and cosmetics industry

    Intercharm Moscow 2023 was held from 25th - 28th October 2023 at Crocus Expo, Moscow, Russian Federation. This was 29th International exhibition for perfumery and cosmetics industry.

  • Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat

    Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.

  • Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

    T cells are soldiers on the front lines of the human immune system. They are responsible for many important roles, including attacking viral- or bacterial-infected cells and certain cancer cells, and immunological memory – remembering the specific pathogens or the cancer signatures that originally trigger T cells.

  • Psoriasis not caused by spontaneous mutations in skin cells

    Psoriasis - a chronic skin condition - is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. The team, from the Wellcome Sanger Institute and collaborators, sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated genes in the psoriatic patches that weren’t also mutated in the individual’s unaffected skin tissue.

  • SMT announces positive results of S-Flex UK-II Registry at TCT 2023

    Study synopsis
    - The trial was presented on October 25, 2023 in the PCI Outcomes III session in San Francisco.
    - 1835 patients were studied across 19 study centres in UK

    SMT (Sahajanand Medical Technologies), a pioneering healthcare company in India with a focus on innovative patient care in the cardiovascular sector, is pleased to announce promising data from its study, the Prospective S-FLEX UK-II Registry.

Subscribe to Pharma News